Composition for promoting ketone body production
Provided is a composition for promoting ketone body production that comprises a water insoluble polymer of a β-hydroxy short-medium chain fatty acid such as homopolymer of β-hydroxybutyric acid or a copolymer of β-hydroxybutyric acid and β-hydroxyvaleric acid. The composition is useful for the treatment or prevention of a disease or condition that can be treated by promoting ketone body production.
1. A method for treating cerebral stroke in a subject in need thereof, comprising:
administering a water insoluble polymer of β-hydroxy short-medium chain fatty acid to the subject in need thereof, wherein
the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is a homopolymer of β-hydroxybutyric acid or a copolymer of β-hydroxybutyric acid and a saturated β-hydroxy fatty acid having 3-12 carbon atoms,
the weight average molecular weight of the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is in the range of 13,600-20,000,000, and
the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is administered orally, via a transnasal tube, or by gastric administration.
2. The method of claim 1 , wherein the saturated β-hydroxy fatty acid having 3-12 carbon atoms is selected from the group consisting of: β-hydroxypropionic acid, β-hydroxyvaleric acid, β-hydroxycaproic acid, β-hydroxycaprylic acid, β-hydroxycapric acid, and a mixture thereof.
3. The method of claim 1 , wherein the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is a homopolymer of β-hydroxybutyric acid.
4. The method of claim 1 , wherein the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is a copolymer of β-hydroxybutyric acid and β-hydroxyvaleric acid.
5. The method of claim 1 , wherein the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is produced by spirulina.
6. The method of claim 1 , wherein the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is administered orally.
7. The method of claim 6 , wherein the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is administered in the form of animal feedstuff or an additive for animal feedstuff.
8. The method of claim 6 , wherein the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is administered in the form of a functional food product.
9. The method of claim 6 , wherein the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is administered in the form of a pharmaceutical composition.
10. The method of claim 1 , wherein the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is orally administered for at least two weeks to the subject.
11. A method for promoting recovery from an after-effect of cerebral stroke in a subject in need thereof, comprising:
administering a water insoluble polymer of a β-hydroxy short-medium chain fatty acid to the subject in need thereof, wherein
the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is a homopolymer of β-hydroxybutyric acid or a copolymer of β-hydroxybutyric acid and a saturated β-hydroxy fatty acid having 3-12 carbon atoms,
the weight average molecular weight of the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is in the range of 13,600-20,000,000, and
the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is administered orally, via a transnasal tube, or by gastric administration.
12. A method for reducing the severity of cerebral stroke in a subject in need thereof, comprising:
administering a water insoluble polymer of β-hydroxy short-medium chain fatty acid to the subject in need thereof, wherein
the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is a homopolymer of β-hydroxybutyric acid or a copolymer of β-hydroxybutyric acid and a saturated β-hydroxy fatty acid having 3-12 carbon atoms,
the weight average molecular weight of the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is in the range of 13,600-20,000,000, and
the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is administered orally, via a transnasal tube, or by gastric administration.
13. The method of claim 1 , wherein 1 mg/kg to 500 mg/kg of the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is orally administered to the subject per day.
14. The method of claim 11 , wherein 1 mg/kg to 500 mg/kg of the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is orally administered to the subject per day.
15. The method of claim 12 , wherein 1 mg/kg to 500 mg/kg of the water insoluble polymer of a β-hydroxy short-medium chain fatty acid is orally administered to the subject per day.